20 results

Several companies in which Neil Woodford invests have also been targeted by hedge funds. Photograph: Woodford Investment Management/PA Wire

Hedge funds are circling Neil Woodford’s investment trust, along with several companies he invests in, as the fallout from the trading freeze on his (...)

As part of the new deal, Theravance is to receive an upfront payment of $100m and will be eligible to receive up to an additional $900m in potential payments

Dublin-based Theravance Biopharma Ireland, has signed a new deal with pharma giant Janssen to develop a treatment for inflammatory intestinal diseases(...)

Japan’s benchmark Nikkei 225 Stock Average surged 7.7 per cent, gaining more than 1,300 points, as sentiment was bolstered by  rallies on Wall Street and optimism on China economy. Photograph: . Franck Robichon/EPA

Global markets continued to respond to positive developments in China. In the US, stocks struggled to add to their second best rally of the year, even(...)

Elan chairman Robert Ingram at the company’s EGM in Dublin today. Photograph: Aidan Crawley

Elan shareholders decisively rejected a major investment programme proposed by the company at a special meeting in Dublin today.However, investors nar(...)

Royalty Pharma’s $6.7 billion offer for Irish pharmacuetical firm Elan has now lapsed

Pharmaceutical firm Elan has initiated a formal sale process following the approval this morning of its share buyback programme. In accordance with(...)

Royalty Pharma’s hostile bid for Irish pharmaceutical firm Elan continues as its chairman asserts that “no other bona fide buyer” is interested in Elan. (Photo:John Cogill/Bloomberg News)

Ahead of Elan’s egm later today, at which shareholders will vote on a series of acquisitions undertaken by the Irish pharmaceutical firm, the chairman(...)

Elan chief executive Kelly Martin: the firm faces a critical moment in its volatile history with tomorrow’s EGM.

Irish biotech group Elan has been through many critical moments in its volatile history. Tomorrow, shareholders gather for an extraordinary general me(...)

Elan shareholders vote on four proposed investments by the company at an EGM on Monday.Photographer: Dara Mac Dónaill

A High Court judge has granted an injunction effectively keeping alive Royalty Pharma’s $6.7 billion offer for Elan pending the outcome of a full lega(...)

While Royalty Pharma boosted its unsolicited offer to as much as $15.50 a share this month, at least five analysts covering Dublin-based Elan see the stock falling if that bid disappears

Elan shareholders risk losing $2 billion by listening to the company’s board and rejecting Royalty Pharma’s takeover bid, according to market analysts(...)

On Monday, shareholders gather in Dublin, potentially to decide the fate of the company

Shareholders at Elan have seen a lot through the years. But even they must be nonplussed by the frantic claim and counterclaim being put about by the (...)

  • 1
  • 2
  • Next
  • Last »